Payment overview · 2025
General Payments
$841.95
33 reported records · 18 companies
Healthcare provider profile · identity verified
Amit K Dua, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CUMMING, GA · NPI 1639131691
Verified facts
What the public records show
CMS Open Payments records show Amit K Dua, M.D. received $841.95 in general payments during 2025 across 33 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 15.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $130.07 | 15.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $115.95 | 13.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $95.01 | 11.3% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $62.53 | 7.4% | 3 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.24 | 7.3% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $55.97 | 6.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.72 | 5.4% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $44.24 | 5.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $36.89 | 4.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $35.11 | 4.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $25.01 | 3.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.87 | 3.0% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $23.91 | 2.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.93 | 2.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $20.08 | 2.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.87 | 1.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.70 | 1.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.85 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $841.95 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $155.08 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $115.95 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $61.24 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $55.97 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $45.82 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $44.24 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $42.97 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $39.61 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $36.89 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $35.11 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $26.51 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $24.87 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.87 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 206 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 56 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 88 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
135 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
88 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
206 | 50 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 653 | 155 |
| Amlodipine Besylate | Amlodipine Besylate | 569 | 155 |
| Atorvastatin Calcium | Atorvastatin Calcium | 525 | 134 |
| Omeprazole | Omeprazole | 417 | 124 |
| Gabapentin | Gabapentin | 413 | 126 |
| Quetiapine Fumarate | Quetiapine Fumarate | 401 | 105 |
| Alprazolam | Alprazolam | 377 | 63 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 317 | 54 |
| Losartan Potassium | Losartan Potassium | 315 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 314 | 86 |
| Dexamethasone | Dexamethasone | 280 | 174 |
| Tamsulosin Hcl | Tamsulosin Hcl | 278 | 71 |
| Trazodone Hcl | Trazodone Hcl | 256 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 255 | 68 |
| Lisinopril | Lisinopril | 251 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 235 | 73 |
| Furosemide | Furosemide | 224 | 75 |
| Sertraline Hcl | Sertraline Hcl | 215 | 54 |
| Eliquis | Apixaban | 206 | 50 |
| Fluoxetine Hcl | Fluoxetine Hcl | 200 | 52 |
| Metformin Hcl | Metformin Hcl | 183 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 180 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 179 | 46 |
| Carvedilol | Carvedilol | 176 | 41 |
| Memantine Hcl | Memantine Hcl | 170 | 35 |
| Montelukast Sodium | Montelukast Sodium | 164 | 42 |
| Donepezil Hcl | Donepezil Hcl | 155 | 33 |
| Azithromycin | Azithromycin | 149 | 117 |
| Potassium Chloride | Potassium Chloride | 143 | 48 |
| Bupropion Xl | Bupropion Hcl | 138 | 36 |
| Farxiga | Dapagliflozin Propanediol | 135 | 24 |
| Mirtazapine | Mirtazapine | 134 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 47 |
| Lorazepam | Lorazepam | 122 | 98 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 119 | 98 |
| Glipizide | Glipizide | 114 | 37 |
| Aripiprazole | Aripiprazole | 113 | 21 |
| Tramadol Hcl | Tramadol Hcl | 108 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 106 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 99 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 98 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 96 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 32 |
| Simvastatin | Simvastatin | 94 | 32 |
| Levetiracetam | Levetiracetam | 89 | 20 |
| Ozempic | Semaglutide | 88 | 22 |
| Finasteride | Finasteride | 85 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 25 |
| Ondansetron Odt | Ondansetron | 83 | 38 |
| Famotidine | Famotidine | 81 | 27 |
| Januvia | Sitagliptin Phosphate | 80 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 80 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 19 |
| Diazepam | Diazepam | 77 | 15 |
| Spironolactone | Spironolactone | 77 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 22 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 65 | 11 |
| Morphine Sulfate | Morphine Sulfate | 65 | 61 |
| Clonazepam | Clonazepam | 63 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 60 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 58 | 51 |
| Levofloxacin | Levofloxacin | 57 | 46 |
| Jardiance | Empagliflozin | 56 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | suppressed |
| Fluconazole | Fluconazole | 55 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 17 |
| Risperidone | Risperidone | 54 | 11 |
| Torsemide | Torsemide | 52 | 21 |
| Allopurinol | Allopurinol | 50 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 18 |
| Digoxin | Digoxin | 47 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 47 | 11 |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Temazepam | Temazepam | 45 | 18 |
| Alendronate Sodium | Alendronate Sodium | 44 | suppressed |
| Ezetimibe | Ezetimibe | 44 | suppressed |
| Glimepiride | Glimepiride | 43 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 42 | 17 |
| Synthroid | Levothyroxine Sodium | 42 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 13 |
| Nifedipine Er | Nifedipine | 41 | 12 |
| Midodrine Hcl | Midodrine Hcl | 39 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 12 |
| Pregabalin | Pregabalin | 37 | 13 |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Metronidazole | Metronidazole | 36 | 26 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 26 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 23 |
| Atenolol | Atenolol | 32 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Methimazole | Methimazole | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Prednisone | Prednisone | 30 | 18 |
| Olanzapine | Olanzapine | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 12 |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 23 | suppressed |
| Haloperidol | Haloperidol | 23 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 21 | suppressed |
| Brilinta | Ticagrelor | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Lacosamide | Lacosamide | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 12 |
| Febuxostat | Febuxostat | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 14 |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Methadone Hcl | Methadone Hcl | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 16 |
| Dutasteride | Dutasteride | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 16 | 14 |
| Baclofen | Baclofen | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 15 | 14 |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $841.95 · 33 records | Otsuka America Pharmaceutical, Inc. | AIRSUPRA, AREXVY, CAPLYTA, CAPVAXIVE, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, GARDASIL 9, INSPIRE, JARDIANCE, Leqembi, NUPLAZID, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VRAYLAR, Veozah, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error